

KIRA PHARMACEUTICALS APPOINTS ANGELA YAN AS PRESIDENT OF CHINA AND ASIA DEVELOPMENT AND OPERATIONS

CAMBRIDGE, MA, USA and SUZHOU, JIANGSU, CHINA (August 1, 2022) – Kira Pharmaceuticals, a global clinical-stage biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced the appointment of Angela (Hui) Yan as President of China and Asia Development and Operations. In this role, Ms. Yan will lead Kira’s China division, overseeing clinical development execution and strategy as well as operational excellence for China and Asia.

“We are excited to welcome a leader of Angela’s caliber to oversee our China and Asia business,” said Frederick Beddingfield, MD, PhD, CEO of Kira Pharmaceuticals. “With extensive experience spearheading business development and operations, Angela’s background and talents will support Kira’s efforts as we work to translate our deep understanding of the complement system to deliver transformative treatments for patients.”

Ms. Yan joins Kira after over four years at Clinical CRO dMED-Clinipace, where she held a number of senior leadership positions including China President and Chief Operating Officer. She took full business responsibility in China and led operations and development efforts, building business management systems to increase operational efficiency and achieve sustainable growth. Prior to these roles, Ms. Yan served as Senior Director for R&D and Regulatory at R&D based Pharmaceutical Association Committee (RDPAC) in China, leading and engaging China R&D and Regulatory policy sharing to promote an innovation ecosystem and quality improvement, and supporting China to join ICH and becoming a member of ICH management committee. She also held several critical positions in global pharmaceutical companies including serving as the Regulatory Head for Asia Pacific, Millennium (Takeda Oncology) Asia Development Center, Regulatory Head for BMS China, and Regulatory Head of GSK China.

“I am eager to join this world-class team of seasoned business strategists and drug developers,” said Ms. Yan. “With Phase 2 trials about to begin for the lead asset, KP104, across multiple indications, it is an incredibly exciting time for the company, and I look forward to taking part in this effort.”

Ms. Yan started her career as a neurologist in Beijing Tian Tan Hospital, after receiving her MD from Capital Medical University in Beijing. She also holds an EMBA from the Sino-Europe International Business School.

About Kira Pharmaceuticals

Kira Pharmaceuticals is a global clinical-stage biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases. Enabled by its LOGIC platform, the company has developed a pipeline of nine (9) novel assets spanning targets across the complement cascade. Kira is committed to advancing life-changing therapies that will transform the lives of patients globally with complement-driven diseases. Kira Pharmaceuticals is headquartered in Cambridge, Massachusetts with additional offices in Suzhou and Shanghai, China. More information on Kira can be found at www.kirapharma.com and on [LinkedIn](#).

Media Contact

Sarah O'Connell

Verge Scientific Communications

soconnell@vergescientific.com

科越医药任命闫慧女士为中国及亚洲区研发与运营总裁

美国马萨诸塞州剑桥市和中国江苏省苏州市(2022年8月1日)-- 科越医药，一家致力于研发新一代补体靶向疗法治疗免疫介导疾病领域的先驱、处于临床研发阶段的全球化生物技术公司，今天宣布：公司任命闫慧女士(Angela Yan)为科越医药中国及亚洲区研发与运营总裁。闫慧女士(Angela Yan)将负责领导科越医药中国团队，全面负责公司在中国及亚洲地区的临床开发战略和执行、以及卓越运营管理事务。

科越医药首席执行官、医学博士 Frederick Beddingfield 表示：“我们非常激动，欢迎 Angela 这样优秀的领导人才加入我们并负责我们中国及亚洲地区的业务。Angela 在业务开发和企业运营方面经验丰富，在科越医药不断加深对补体领域的探索从而向患者提供靶向疗法的过程中，她的工作背景和才能将为科越医药提供强有力的帮助”。

在加入科越医药之前，闫慧女士(Angela Yan)在 dMED-Clinipace 工作四年多，曾担任该公司多个重要管理职务，包括中国区总裁和首席运营官等高级管理职位，全面负责该公司中国区的业务运营和开发管理，改善业务管理系统以提高运营效率，并取得业务健康持续增长。在此之前，闫慧女士曾担任中国外商投资企业协会药品研制和开发行业委员会(RDPAC)的研发与法规高级总监，积极推动中国药品研发创新生态系统的建立、监管法规与国际接轨及研发质量的改进。与此同时支持中国加入 ICH 并成为 ICH 管委会成员。此外，闫慧女士还曾在数家国际化制药公司担任重要职位，曾在 Millennium(武田肿瘤)亚洲开发中心担任亚太区法规负责人、在 BMS 中国担任法规负责人，以及在 GSK 中国担任法规负责人。

闫慧女士表示：“我很荣幸能加入这个世界一流、由经验丰富的企业战略家和药物研发人才组成的优秀团队。公司针对多种适应症的主导产品 KP104 的 2 期临床试验即将开始，这是令人振奋的时刻。我非常期待和大家一起为之努力”。

闫慧女士毕业于北京的首都医科大学，获医学学位(MD)，随后在北京天坛医院任神经科专家。此外，她还拥有中欧国际工商学院的高级工商管理硕士学位(EMBA)。

关于科越医药

科越医药是一家处于临床研发阶段的全球化生物技术公司，也是补体靶向疗法治疗免疫介导疾病的先驱。公司凭借自己的 LOGIC 药物发现平台，以克服补体药物开发过程中的各种挑战，致力于推进首创疗法(FIC)及同类最佳疗法(BIC)，公司已经开发出针对补体靶点的九种创新管线。科越医药致力于开发针对补体介导疾病的突破性免疫疗法，以此彻底改善补体驱动型疾病患者的生活。科越医药总部位于美国马萨诸塞州剑桥，并且在中国苏州和上海设有办公室和研发中心。如需了解有关科越医药的更多信息，请访问公司官网 www.kirapharma.com 和关注 LinkedIn。